Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sanofi (OTC: SNYNF).

Full DD Report for SNYNF

You must become a subscriber to view this report.


Recent News from (OTC: SNYNF)

It Affects Over 1.5 Million People in the UK. [1],[2] In a Survey, 80% Report that it Impacts their Mood, Mental Health and Well-Being. But What is Atopic Dermatitis?
GUILDFORD, England , May 15, 2018 /PRNewswire/ -- Not intended for Irish media Atopic dermatitis is the most common type of eczema [3] New public awareness campaign  Scratch Beneath the Surface  uncovers the real impact of atopic dermatitis UK-wide survey of people wi...
Source: PR Newswire
Date: May, 15 2018 02:00
'Safer' Dividend Healthcare Top Gainers Are AbbVie, Sanofi, Lilly, Gilead, & Novartis (All BPh) Per Broker Targets To April 2019
Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend Stocks to Net 15.6% to 33.7% Gains To April, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming year....
Source: SeekingAlpha
Date: April, 10 2018 13:25
Dividend Gainers: Sanofi, Lilly, Johnson & Johnson, & Gilead Are Tops Per Broker Targets To February 2019
Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.95% to 26.43% Gains To February, 2019 Six of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y...
Source: SeekingAlpha
Date: March, 01 2018 16:59
Big Pharma Rules 'Safer' Dividend Healthcare Top Gains Per Broker Targets To January
Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.64% to 13.34% Gains To January, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y...
Source: SeekingAlpha
Date: January, 28 2018 13:13
Boulder Growth & Income Fund Is At Least 5% Overvalued And A Poor Long-Term Holding
Boulder Growth & Income Fund ( BIF ) has seen some pretty positive coverage recently (respectably here , here and here ). These articles are written by some popular authors, some of whom I think are fairly skilled and write great articles. My personal opinion after analysis of Boulde...
Source: SeekingAlpha
Date: July, 24 2017 20:32
Sanofi Receives CHMP Positive Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
GUILDFORD, England , July 21, 2017 /PRNewswire/ -- FOR UK MEDIA ONLY First investigational targeted biologic in the European Union to receive positive CHMP opinion for atopic dermatitis  Sanofi and its specialty care global business unit, Sanofi Genzyme, today announced that th...
Source: PR Newswire
Date: July, 21 2017 08:07
Sanofi Announces Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union
DUBLIN , June 27, 2017 /PRNewswire/ -- - Marketing authorisation for sarilumab offers a new treatment option for people in Ireland living with the debilitating effects of RA - Sanofi and its specialty care global business unit, Sanofi Genzyme, announ...
Source: PR Newswire
Date: June, 27 2017 01:47
Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union
GUILDFORD, England , June 27, 2017 /PRNewswire/ -- - Marketing authorisation for sarilumab offers a new treatment option for people in the UK living with the debilitating effects of RA - Sanofi and its specialty care global business unit, Sanofi Genzyme, announc...
Source: PR Newswire
Date: June, 27 2017 01:45
Start Your Morning With a Cup of Coffee and an Ounce of Dengue Prevention
SINGAPORE , June 15, 2017 /PRNewswire/ --  Sanofi Pasteu r , the vaccines global business unit of  Sanof i , today launched the 'Be A Wall Against Dengue' disease education campaign in Singapore , part of the company's continue...
Source: PR Newswire
Date: June, 14 2017 18:30
UK Patients Granted Early Access to Sanofi's Innovative Dermatology Treatment Dupilumab by MHRA
GUILDFORD, England , March 14, 2017 /PRNewswire/ -- P ositive scientific opinion under Early Access to Medicines Scheme (EAMS) recognises burden of severe atopic dermatitis and the significant unmet need of patients   ...
Source: PR Newswire
Date: March, 14 2017 04:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1482.739882.739882.739882.73981,209
2018-08-1383.841183.841183.841183.841112,729
2018-08-1082.6082.6082.6082.602,233
2018-08-0986.1586.1586.1586.15200
2018-08-08N/A88.4097N/AN/A24,855

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-09200200100.0000Short
2018-08-079090100.0000Short
2018-07-1935954565.8716Short
2018-07-167017140.9357Short
2018-07-1260060599.1736Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SNYNF.


About Sanofi (OTC: SNYNF)

Logo for Sanofi (OTC: SNYNF)

Not available

 

Contact Information

 

 

Current Management

  • JeanFrancois Dehecq / CEO
  • Hanspeter Spek / COO
  • Pierre Lepienne / Secretary

Current Share Structure

     


    Recent Filings from (OTC: SNYNF)

    Post-effective amendment to an S-8 filing
    Filing Type: S-8 POSFiling Source: edgar
    Filing Date: May, 15 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 03 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 27 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 24 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 18 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 03 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 29 2018
    Amendment to a previously filed 20-F
    Filing Type: 20-F/AFiling Source: edgar
    Filing Date: March, 16 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 15 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 12 2018

     

     


    Daily Technical Chart for (OTC: SNYNF)

    Daily Technical Chart for (OTC: SNYNF)


    Stay tuned for daily updates and more on (OTC: SNYNF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: SNYNF)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SNYNF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SNYNF and does not buy, sell, or trade any shares of SNYNF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/